Overview

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of SHR-2173 in Patients With Systemic Lupus Erythematosus

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
To investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple subcutaneous injections of SHR-2173 in patients with systemic lupus erythematosus (SLE).
Phase:
PHASE1
Details
Lead Sponsor:
Guangdong Hengrui Pharmaceutical Co., Ltd